Three-dimensional prostate cancer organoids represent a promising platform
for modeling tumor biology and personalizing therapeutic strategies. However, unlike
many other solid tumors, reproducing this pathology in vitro is challenging. Despite initial
culture establishment rates reaching 70-90% in certain studies, most cultures undergo
early growth arrest (typically within passages P1-P3 or the first 1-2 months), accompanied
by a high risk of losing the target tumor clone. In the present work, we provide a
critical analysis of the current state of 3D prostate cancer culture technologies and attempt
to identify the fundamental reasons for the inefficiency of standard multicomponent
media and traditional extracellular matrices. Based on the analysis of single-cell
transcriptomic profiling data, we characterized the adaptive drift of organoid cellular
composition toward basal and transient states. Furthermore, we substantiated the critical
need to modernize approaches for confirming model relevance, particularly by analyzing
in detail the limitations of traditional markers. As an effective solution, we propose
the concept of integrating multiplex expression test systems based on accessible quantitative
PCR platforms, utilizing the extensive arsenal of highly informative RNA biomarkers
accumulated in clinical urologic oncology. We conclude that the transition from empirical
condition selection to directed niche reconstruction based on single-cell analysis
data combined with PCR verification will open new opportunities for the widespread implementation
of organoid models in basic research and clinical practice.